Sanofi presents results from the first head-to-head study comparing Toujeo® (insulin glargine 300 units/mL (Gla-300)) to insulin degludec

Sanofi presented non-inferiority results of the first ever head-to-head clinical study comparing its long-acting insulin Toujeo® (Gla-300) to insulin degludec. Results of the study, called BRIGHT, were presented today at the American Diabetes Association (ADA) 78th Scientific Sessions in Orlando, Florida, U.S.[i]

In the study, involving nearly 1,000 patients with type 2 diabetes, Gla-300 met its primary endpoint of non inferior reduction in HbA1 levels versus insulin degludec (at a non-inferiority margin of 0.3% and difference between treatments: -0.05% [95% CI −0.15 to 0.05%]). Gla-300 also demonstrated a lower rate of ‘anytime (24h) hypoglycemia’ in the first 12 weeks, the sensitive period in which patients and healthcare professionals work to determine the most appropriate individual dose.

During this initial phase, Gla-300 lowered both confirmed incidence of hypoglycemia (low blood sugar events) and the rate (number of events) of ‘anytime (24h) hypoglycemia’ (defined as (≤70 mg/dL). At that time, Gla-300 reduced the incidence of hypoglycemia by 26 percent and rate by 23 percent compared to insulin degludec.1

The incidence of hypoglycemia (<70mg/dl) during the full 24 week study period was comparable between Gla-300 and insulin degludec (66.5 vs 69% respectively).